Genenta Science, a Milan biotech, raised $14.6 million in its third funding, led by Shanghai’s Qianzhan Investment Management (QZ) and Fidim, an Italian family fund. Genenta is developing gene therapies for cancer using autologous hematopoietic stem progenitor cells (HSPCs) that contain an engineered gene for a tumor-related cytokine. It aims to trigger interferon-α expression, preventing relapses by rebuilding the patient’s immune system within the tumor. The company’s lead product is Temferon, which has started trials in patients with early relapse multiple myeloma and newly diagnosed glioblastoma multiforme. Source: China Biotoday
